CTX.TO - Crescita Therapeutics Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.9000
0.0000 (0.00%)
As of 2:27PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.9000
Open0.8900
Bid0.9000 x 0
Ask0.9100 x 0
Day's Range0.8900 - 0.9200
52 Week Range0.3850 - 0.9200
Volume19,975
Avg. Volume34,161
Market Cap18.914M
Beta (3Y Monthly)2.26
PE Ratio (TTM)6.62
EPS (TTM)0.1360
Earnings DateMar 27, 2019 - Apr 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group9 days ago

    Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

    Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

  • PR Newswire9 days ago

    Crescita Therapeutics Reports 2019 First Quarter Results

    LAVAL, QC, May 15, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (CTX.TO) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today reported its financial results for the first quarter ended March 31, 2019.

  • PR Newswire17 days ago

    Crescita Therapeutics Strengthens Leadership Team with New Vice-President in Aesthetic and Cosmeceutical Business Unit

    LAVAL, QC, May 7, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (CTX.TO) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, is very pleased to announce that Mr. Jean Colas has joined Crescita as Vice-President of its Aesthetic and Cosmeceutical business unit. Jean's responsibilities will encompass sales team leadership, brand awareness, go-to-market strategy, marketing communications, and customer service. "Jean is a great addition to the Crescita team and knows what it takes to deliver both brand and client success," said Serge Verreault, President and CEO of Crescita.

  • Did Crescita Therapeutics's (TSE:CTX) Share Price Deserve to Gain 73%?
    Simply Wall St.29 days ago

    Did Crescita Therapeutics's (TSE:CTX) Share Price Deserve to Gain 73%?

    If you want to compound wealth in the stock market, you can do so by buying an index fund. But investors can boost returns by picking market-beating companies to own shares in. For example, the Crescita Therapeutics Inc. (TSE...

  • PR Newswire29 days ago

    Crescita Therapeutics Signs Pliaglis® Out-Licensing Agreement with Cantabria Labs for €2.5M Upfront After Reacquiring Rest-of-World Rights

    LAVAL, QC, April 25, 2019 /PRNewswire/ - Crescita Therapeutics Inc. ("Crescita" or the "Company") (TSX: CTX and OTC US: CRRTF), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, is pleased to announce that it has entered into a commercialization license agreement (the "Agreement") with Cantabria Labs, granting Cantabria Labs the exclusive rights to sell and distribute Pliaglis in Italy, Portugal, France and Spain (together the "Territories").

  • PR Newswirelast month

    Crescita Therapeutics to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference in Toronto

    LAVAL, QC, April 17, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (CTX.TO) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company, is pleased to announce that its President and CEO, Serge Verreault will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference which will be held from April 30 to May 1, 2019 in Toronto, Ontario. Mr. Verreault will discuss recent business highlights and the Company's growth strategy. Members of Crescita's management team will also be available for one-on-one investor meetings on both days of the conference.

  • PR Newswire2 months ago

    Crescita Therapeutics Reports Fourth Quarter and Fiscal 2018 Results Record Annual Revenue of $16.6M and Adjusted EBITDA of $1.5M Strong Royalties and Sales Milestones

    LAVAL, QC , March 21, 2019 /PRNewswire/ - Crescita Therapeutics Inc. ( TSX: CTX ) (Crescita or the Company), a commercial dermatology company with a portfolio of non-prescription skincare and prescription ...

  • CNW Group4 months ago

    Crescita Therapeutics Inc.™ and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra's Dermatology Product Portfolio

    LAVAL, QC , and ORLEANS, ON , Feb. 4, 2019 /CNW/ - Crescita Therapeutics Inc. ("Crescita") (CTX.TO), a Canadian commercial dermatology company and Tetra Natural Health (NHP), a subsidiary of Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and development, ("Tetra") (TBP.V) (TBPMF) today announced an agreement to develop an enhanced version of Tetra's dermatology portfolio using Crescita's patented transdermal delivery technologies: Multiplexed Molecular Penetration Enhancer ("MMPE™") and DuraPeel™. The primary active ingredient contained in the product portfolio to be reformulated is beta-caryophyllene ("Beta-C"), which is known to work on Cannabidiol ("CBD") 2 receptors.

  • GlobeNewswire4 months ago

    Crescita Therapeutics Inc.™ and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra’s Dermatology Product Portfolio

    Crescita Therapeutics Inc. ("Crescita") (CTX.TO), a Canadian commercial dermatology company and Tetra Natural Health (NHP), a subsidiary of Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and development, ("Tetra") (TBP.V) (TBPMF) today announced an agreement to develop an enhanced version of Tetra’s dermatology portfolio using Crescita’s patented transdermal delivery technologies: Multiplexed Molecular Penetration Enhancer ("MMPE™") and DuraPeel™. The primary active ingredient contained in the product portfolio to be reformulated is beta-caryophyllene ("Beta-C"), which is known to work on Cannabidiol ("CBD") 2 receptors. The testing methodology and the clinical development made possible by the collaboration will help optimize the delivery of Beta-C and several other active ingredients into the skin and local tissues.

  • PR Newswire5 months ago

    U.S. FDA Approves Removal of "Not for Home Use" Label Restriction for Pliaglis®

    LAVAL, QC, Dec. 17, 2018 /PRNewswire/ - Crescita Therapeutics Inc. (CTX.TO) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the Prior Approval Supplement (PAS) for Pliaglis® following its mandated six-month review process, in line with the target action date under the Prescription Drug User Fee Act (PDUFA). In 2017, Taro Pharmaceuticals Inc. (Taro), our licensee for Pliaglis in the U.S. market, completed the study to support the removal of the Pliaglis "Not for Home Use" label restriction and filed the FDA submission with the proposed label change on June 8, 2018.

  • CNW Group6 months ago

    Crescita Therapeutics™ Reports 2018 Third Quarter Results Strong Royalty Revenue and Achievement of First Pliaglis US Sales Milestone Positive Adjusted EBITDA of $0.8M

    Crescita Therapeutics™ Reports 2018 Third Quarter Results Strong Royalty Revenue and Achievement of First Pliaglis US Sales Milestone Positive Adjusted EBITDA of $0.8M

  • Simply Wall St.6 months ago

    What Investors Should Know About Crescita Therapeutics Inc’s (TSE:CTX) Financial Strength

    Investors are always looking for growth in small-cap stocks like Crescita Therapeutics Inc (TSE:CTX), with a market cap of CA$9m. However, an important fact which most ignore is: how financially Read More...

  • PR Newswire6 months ago

    Crescita Reinvigorates Skincare Line Leveraging its MMPE™ Technology and Becomes One of the First Companies Worldwide to Release Anti-Ageing Formulation Using ECOBIOTYS®

    LAVAL, QC, Nov. 8, 2018 /PRNewswire/ - Crescita Therapeutics Inc. (CTX.TO) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, is pleased to announce that it has launched five product innovations in its lead aesthetic skincare brand, Laboratoire Dr Renaud, sold to professional aestheticians and aesthetic schools throughout Canada. The Innovations were launched only six months following the return of Isabelle Villeneuve, an internationally recognized leader in innovation and market intelligence, as head of Strategy, Quality and Innovation.

  • CNW Group7 months ago

    Crescita's Patented Delivery Technologies Demonstrate Enhanced Skin Permeation of Cannabidiol

    LAVAL, QC , Oct. 15, 2018 /CNW/ - Crescita Therapeutics Inc. (CTX.TO) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, is pleased to announce that its patented transdermal delivery technologies: Multiplexed Molecular Penetration Enhancer ("MMPE™") and DuraPeel™ have demonstrated enhanced permeation of Cannabidiol ("CBD"), the non-psychoactive component of cannabis, in a recent in-vitro skin permeation study performed in Franz Diffusion Cells. The study, using human cadaver skin, was performed by an independent Southern California -based laboratory specializing in the transdermal delivery of actives, showed that both MMPE and DuraPeel significantly increased the transdermal permeation of CBD over the control formulation by up to 14- and 6-fold, respectively.